These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 617785)

  • 21. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.
    Herzog RW; Arruda VR; Fisher TH; Read MS; Nichols TC; High KA
    Thromb Haemost; 2000 Aug; 84(2):352-4. PubMed ID: 10959714
    [No Abstract]   [Full Text] [Related]  

  • 22. Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.
    Bray GL; Thompson AR
    J Clin Invest; 1986 Apr; 77(4):1194-200. PubMed ID: 3514676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation.
    Maekawa H; Sugo T; Yamashita N; Kamiya K; Umeyama H; Miura N; Naka H; Nishimura T; Yoshioka A; Matsuda M
    Biochemistry; 1993 Jun; 32(24):6146-51. PubMed ID: 8512923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
    Osterud B; Kasper CK; Prodanos C
    Thromb Res; 1979; 15(1-2):235-43. PubMed ID: 483278
    [No Abstract]   [Full Text] [Related]  

  • 25. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
    Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
    J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.
    Usharani P; Warn-Cramer BJ; Kasper CK; Bajaj SP
    J Clin Invest; 1985 Jan; 75(1):76-83. PubMed ID: 3965513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two allotypes of factor IX present in haemophilia B.
    Ljung R; Wallmark A; Nilsson IM
    Scand J Haematol; 1986 Nov; 37(5):411-6. PubMed ID: 3810038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A simple analytic method of the activation mechanism of factor IX using Western blotting].
    Sakai T; Ohkubo Y; Tanaka I; Yamamoto K; Yoshioka A; Fukui H
    Rinsho Ketsueki; 1987 Jan; 28(1):47-52. PubMed ID: 3573331
    [No Abstract]   [Full Text] [Related]  

  • 29. Three distinct point mutations in the factor IX gene of three Japanese CRM+ hemophilia B patients (factor IX BMNagoya 2, factor IX Nagoya 3 and 4).
    Hamaguchi M; Matsushita T; Tanimoto M; Takahashi I; Yamamoto K; Sugiura I; Takamatsu J; Ogata K; Kamiya T; Saito H
    Thromb Haemost; 1991 May; 65(5):514-20. PubMed ID: 1871712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of hemophilia B in North Indian families: identification of novel and recurrent molecular events in the factor IX gene.
    Mahajan A; Chavali S; Kabra M; Chowdhury MR; Bharadwaj D
    Haematologica; 2004 Dec; 89(12):1498-503. PubMed ID: 15590401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling.
    Miyata T; Kuze K; Matsusue T; Komooka H; Kamiya K; Umeyama H; Matsui A; Kato H; Yoshioka A
    Br J Haematol; 1994 Sep; 88(1):156-65. PubMed ID: 7803238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A genetic variant of factor IX with decreased capacity for Ca2+ binding.
    Bertina RM; Veltkamp JJ
    Br J Haematol; 1979 Aug; 42(4):623-35. PubMed ID: 476013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.
    Wojcik EG; Van Den Berg M; Poort SR; Bertina RM
    Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):629-36. PubMed ID: 9169594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): arginine mutations that preclude zymogen activation.
    Diuguid DL; Rabiet MJ; Furie BC; Furie B
    Blood; 1989 Jul; 74(1):193-200. PubMed ID: 2752109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitive solid phase enzyme immunoassay for factor IX antigen and classification of hemophilia B.
    Takamatsu J; Kamiya T; Ogata K; Sugihara T; Koie K; Kato K
    Haemostasis; 1983; 13(1):9-16. PubMed ID: 6341181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo.
    Monroe DM; McCord DM; Huang MN; High KA; Lundblad RL; Kasper CK; Roberts HR
    Blood; 1989 May; 73(6):1540-4. PubMed ID: 2713493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of normal and abnormal human factor IX with trypsin.
    Monroe DM; Noyes CM; Straight DL; Roberts HR; Griffith MJ
    Arch Biochem Biophys; 1985 May; 238(2):490-6. PubMed ID: 3873217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
    Liebman HA; Limentani SA; Furie BC; Furie B
    Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3879-83. PubMed ID: 2408269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling.
    Vidaud D; Tartary M; Costa JM; Bahnak BR; Gispert-Sanchez S; Fressinaud E; Gazengel C; Meyer D; Goossens M; Lavergne JM
    Hum Genet; 1993 Apr; 91(3):241-4. PubMed ID: 8478007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX.
    Chavali S; Sharma A; Tabassum R; Bharadwaj D
    Proteins; 2008 Oct; 73(1):63-71. PubMed ID: 18393396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.